Sanofi-Aventis's diabetes drug lixisenatide positive in Phase III
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's once daily glucagon-like peptide-1 (GLP-1) injectable agonist lixisenatide has met the primary endpoint of improving glycaemic control in adult patients with type 2 diabetes, top-line Phase III data have revealed.